[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345206-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345206-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cancer-statistics-in-korea-incidence-mortality-survival-and-prevalence-in-2023","Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2023","","National cancer statistics for Korea in 2023 are analyzed across incidence, mortality, survival, and prevalence, with secular trends and international comparisons. Incidence, survival, and prevalence estimates use the Korea National Cancer Incidence Database covering 1999–2023, with survival follow-up through December 31, 2024, while mortality relies on national official data and international benchmarks use GLOBOCAN. Findings report 288,613 new cases and 85,271 cancer deaths in 2023, plus over 2.73 million prevalent cases and stage- and site-specific outcomes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cancer-statistics-in-korea-incidence-mortality-survival-and-prevalence-in-2023/345206/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cancer-statistics-in-korea-incidence-mortality-survival-and-prevalence-in-2023/345206.png","ImageObject",300,407,{"name":42,"@type":43},"Aria","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-08","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What national cancer indicators are reported for Korea in this study for 2023?","Question",{"text":63,"@type":64},"The study reports incidence, mortality, survival, and prevalence in 2023, together with secular trends and international comparisons.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which datasets were used to calculate incidence, survival, and prevalence?",{"text":68,"@type":64},"Incidence, survival, and prevalence rates were calculated using the Korea National Cancer Incidence Database (1999–2023), with survival follow-up until December 31, 2024.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the major 2023 findings on new cases, deaths, and prevalent cases?",{"text":72,"@type":64},"In 2023, 288,613 new cancer cases and 85,271 cancer deaths were reported, and over 2.73 million prevalent cases were identified, representing 5.3% of the Korean population.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345206,1790387600,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":128,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","pISSN 1598-2998, eISSN 2005-9256  \n\n| [https://doi.org/10.4143/crt.2026.298](https://doi.org/10.4143/crt.2026.298) Cancer Res Treat. 2026;58(2):349-367\u003Cbr>\u003Cbr>Special Article\u003Cbr>Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2023\u003Cbr>Eun Hye Park1,2 , Kyu-Won Jung1,2 , Seo Hyun Choi1,2 , Nam Ju Park1,2 , Mee Joo Kang1,2 , E HwaYun1,2 , Hye-Jin Kim1,2 , Jeong-Eun Kim1,2 , Kui Son Choi3,4 , Han-Kwang Yang1,3 , The Community of Population-Based Regional Cancer Registries\u003Cbr>1Korea Central Cancer Registry, National Cancer Center, Goyang, 2Division of Cancer Registration and Surveillance, National Cancer Control Institute, National Cancer Center, Goyang, 3National Cancer Center Graduate School of Cancer Science and Policy, National Cancer Center, Goyang,\u003Cbr>4National Cancer Control Institute, National Cancer Center, Goyang, Korea |  |\n| --- | --- |\n| Purpose The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2023, with international comparisons.\u003Cbr>Materials and Methods Cancer incidence, survival, and prevalence rates were calculated using the Korea National Cancer Incidence Database (1999-2023), with survival follow-up until December 31, 2024. Mortality data were obtained from the Ministry of Data and Statistics, while international comparisons were based on GLOBOCAN data.\u003Cbr>Results In 2023, 288,613 newly diagnosed cancer cases (age-standardized rate [ASR], 288.6 per 100,000) and 85,271 deaths from cancer (ASR, 64.3 per 100,000) were reported. Among the incident cases, 145,452 (50.4%) were aged 65 years or older. Prostate cancer became the most common cancer among men for the first time. The proportion of localized-stage cancers increased from 45.6% in 2005 to 51.8% in 2023. Korea had the lowest cancer mortality among countries with similar incidence rates and the lowest mortality-to-incidence ratios for stomach, colorectal, and breast cancer. The 5-year relative survival rate (2019-2023) was 73.7% overall and 92.7% for localized-stage cancers. Over 2.73 million prevalent cases were identified in 2023, representing 5.3% of the Korean population.\u003Cbr>Conclusion These findings indicate that Korea’s cancer control efforts have contributed to early detection and improved survival outcomes. As Korea enters a super-aged society in 2025, cancer burden will continue to increase, requiring sustained and adaptive cancer control strategies.\u003Cbr>Key words Neoplasms, Incidence, Mortality, Survival, Prevalence, Korea |  |\n| Introduction | comparisons of cancer incidence and mortality to contextualize Korea’s cancer burden in the global landscape. |\n| Cancer is one of the leading causes of death worldwide, with an estimated 19.9 million new cancer cases and 9 mil- |  |\n| lion deaths worldwide in 2022 [1] . In Korea, cancer has been the leading cause of death since 1983 [2] . In response to this | Materials and Methods |\n| public health challenge, the National Plan for Cancer Control | 1. Data sources |\n| was implemented in 1996, and its fifth plan (2026-2030) was | Annual cancer statistics in Korea are calculated using a |\n| announced on February 24, 2026. As a fundamental part of | national and population-based database of cancer occur- |\n| the Plan, the Korea Central Cancer Registry (KCCR) publishes cancer registration statistics every year [3] . The National | rence, the Korea National Cancer Incidence Database (KNCIDB) . Every year, the KCCR collects information on patients |\n| Cancer Screening Program, implemented in 2002, currently | diagnosed with cancer at hospitals across the country dur- |\n| provides screening services for stomach, colorectal, breast, | ing the past year. The data from the previous year is backed |\n| cervical, liver, and lung cancers in Korea [4] . This program | up with information compiled by central and 11 regional |\n| has contributed to sustained increases in the proportion of | cancer regi","cbCais3iegGddbZg","https://ap.wps.com/l/cbCais3iegGddbZg","pdf",1885608,"English","# Purpose\n# Materials and Methods\n## Data sources\n# Results\n# Conclusion\n# Key words","[{\"question\":\"What national cancer indicators are reported for Korea in this study for 2023?\",\"answer\":\"The study reports incidence, mortality, survival, and prevalence in 2023, together with secular trends and international comparisons.\"},{\"question\":\"Which datasets were used to calculate incidence, survival, and prevalence?\",\"answer\":\"Incidence, survival, and prevalence rates were calculated using the Korea National Cancer Incidence Database (1999–2023), with survival follow-up until December 31, 2024.\"},{\"question\":\"What were the major 2023 findings on new cases, deaths, and prevalent cases?\",\"answer\":\"In 2023, 288,613 new cancer cases and 85,271 cancer deaths were reported, and over 2.73 million prevalent cases were identified, representing 5.3% of the Korean population.\"}]","Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2023 | PDF",1790056777,48,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/03a48263208075daf9d0688de3b9258a.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d4e6766b695f4675aad0b7f29b4d379e.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4bd555ef674267fbc1c1999b8876f210.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0d64ead688291518a056ed92f58e91da.webp",980,1306]